Journal
ACTA NEUROPATHOLOGICA
Volume 125, Issue 2, Pages 201-213Publisher
SPRINGER
DOI: 10.1007/s00401-012-1062-9
Keywords
Amyloid precursor protein; Autosomal-dominant Alzheimer disease; beta-Site APP-cleaving enzyme; Presenilin; beta-Amyloid
Categories
Funding
- Instituto de Salud Carlos III [FIS/PI100018, FIS/PI080036]
- CIBERNED
- Joint Programming for Neurodegenerative Diseases-BIOMARKAPD
Ask authors/readers for more resources
Autosomal-dominant Alzheimer disease (ADAD) is a genetic disorder caused by mutations in Amyloid Precursor Protein (APP) or Presenilin (PSEN) genes. Studies from families with ADAD have been critical to support the amyloid cascade hypothesis of Alzheimer disease (AD), the basis for the current development of amyloid-based disease-modifying therapies in sporadic AD (SAD). However, whether the pathological changes in APP processing in the CNS in ADAD are similar to those observed in SAD remains unclear. In this study, we measured beta-site APP-cleaving enzyme (BACE) protein levels and activity, APP and APP C-terminal fragments in brain samples from subjects with ADAD carrying APP or PSEN1 mutations (n = 18), patients with SAD (n = 27) and age-matched controls (n = 22). We also measured sAPP beta and BACE protein levels, as well as BACE activity, in CSF from individuals carrying PSEN1 mutations (10 mutation carriers and 7 non-carrier controls), patients with SAD (n = 32) and age-matched controls (n = 11). We found that in the brain, the pattern in ADAD was characterized by an increase in APP beta-C-terminal fragment (beta-CTF) levels despite no changes in BACE protein levels or activity. In contrast, the pattern in SAD in the brain was mainly characterized by an increase in BACE levels and activity, with less APP beta-CTF accumulation than ADAD. In the CSF, no differences were found between groups in BACE activity or expression or sAPP beta levels. Taken together, these data suggest that the physiopathological events underlying the chronic A beta production/clearance imbalance in SAD and ADAD are different. These differences should be considered in the design of intervention trials in AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available